Drug Profile
TGN 167
Alternative Names: TGN-167Latest Information Update: 15 Apr 2010
Price :
$50
*
At a glance
- Originator Trigen Holdings AG
- Class Anticoagulants; Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 21 Feb 2008 No development reported - Phase-I for Thrombosis in United Kingdom (PO)
- 31 May 2005 ProCorde GmbH has merged with Trigen Holdings plc to form Trigen Holdings AG
- 24 Nov 2004 Trigen and Eurand have entered into an agreement to co-develop controlled-release formulations of TGN 167